Showing results (1641-1650 of 6,884) with videos related to

Sort By:
Pageof 689
Leukemia Research|November 12, 2025
Differential impact of graft-versus-host disease on post-transplant outcomes of chronic myelomonocytic leukemia according to transplant proceduresHidehiro Itonaga, Yasushi Miyazaki, Machiko Fujioka, et al.
Leukemia Research|June 24, 2025
Assessing the associations of blood metabolites with myelodysplastic syndrome: A bidirectional mendelian randomization studyKeyue Hu, Yiquan Cheng, Gangfeng Xiao, et al.
Leukemia Research|September 20, 2025
Pathogenic mechanisms and targeted therapies for anemia in myelodysplastic syndromesDoudou Chang, Linhua Yang, Ruijuan Zhang
Leukemia Research|June 6, 2025
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)Brian A Jonas, Samantha C Fisch, Peter T Curtin, et al.
Leukemia Research|March 7, 2024
Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteinsHaruka Sudo, Yasuhiro Tonoyama, Emi Ikebe, et al.
Leukemia Research|February 9, 2024
Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvementHannah Goulart, Dahniel Sastow, Erin Moshier, et al.
Leukemia Research|March 13, 2024
Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell linesMara N Zeissig, Duncan R Hewett, Krzysztof M Mrozik, et al.
Leukemia Research|March 9, 2024
Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemiaGarrett Bourne, Kendall Diebold, Manuel Espinoza-Gutarra, et al.
Leukemia Research|March 9, 2024
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemiaSharon Zhong, Heena Kurish, Robert Walchack, et al.
Leukemia Research|July 4, 2024
Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AMLStephanie Boisclair, Edward Zhou, Phyu Naing, et al.
Pageof 689